Related Experiment Video
Updated: Jan 6, 2026
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
PRMT5 Inhibition Hits a Nerve (Sheath Tumor): A Targeted Strategy for MPNSTs
Alexa P Sheehan1,2, Akshaya Warrier1,2, Rebecca D Dodd1,2
1Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.
Abstract:
Protein arginine methyltransferase 5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells. Synthetic lethality approaches using MTAP-cooperative protein arginine methyltransferase 5 inhibitors offer a compelling strategy that selectively targets cancer cells in nerve sheath sarcomas and other MTAP-deleted tumors. See related article by Zhang et al., p. 4779.
Insights
Protein arginine methyltransferase 5 inhibitors show cancer promise but cause toxicity. Synthetic lethality strategies targeting MTAP-deleted tumors, like nerve sheath sarcomas, offer a selective approach to cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Protein arginine methyltransferase 5 (PRMT5) inhibitors are investigated for cancer therapy.
- Clinical development faces challenges due to toxicity in normal cells.
- Synthetic lethality offers a targeted approach to cancer treatment.
Purpose of the Study:
- To explore the therapeutic potential of MTAP-cooperative PRMT5 inhibitors.
- To evaluate the selective targeting of cancer cells with MTAP deletions.
- To address the toxicity limitations of current PRMT5 inhibitors.
Main Methods:
- Utilizing synthetic lethality principles.
- Developing and testing MTAP-cooperative PRMT5 inhibitors.
- Assessing efficacy in cancer models, including nerve sheath sarcomas.
Main Results:
- MTAP-cooperative PRMT5 inhibitors demonstrate selective toxicity towards MTAP-deleted cancer cells.
- This approach mitigates toxicity to normal cells, enhancing therapeutic index.
- Successful targeting observed in relevant cancer types.
Conclusions:
- Synthetic lethality with MTAP-cooperative PRMT5 inhibitors is a viable strategy for treating MTAP-deleted cancers.
- This approach overcomes key toxicity hurdles in PRMT5 inhibitor development.
- Further clinical investigation is warranted for these targeted therapies.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
